NAD footcare case
This article was originally published in The Tan Sheet
Executive SummaryProfoot Footcare Products' labeling claim that Triad Insoles "relieves knee, leg and back pain" should be discontinued due to lack of supporting scientific evidence, National Advertising Division says in recent NAD Case Reports. Dr. Scholl's marketer Schering-Plough challenged the claim, asserting it is "unqualified and overly broad as it does not distinguish" between different types of pain. Although Profoot explained the Triad design "incorporates a cupped heel for foot stability and an anatomically conforming supportive arch" to alleviate joint pressure, NAD agrees with Schering based on lack of clinical data. Profoot, while disagreeing, said it would amend the claim in future packaging...
You may also be interested in...
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
New real-world data, presented at a recent diabetes conference in Madrid, showed that Abbott's FreeStyle Libre system provided several clinical benefits for patients with diabetes.